163 related articles for article (PubMed ID: 18325064)
1. The morbidity of transperineal template-guided prostate mapping biopsy.
Merrick GS; Taubenslag W; Andreini H; Brammer S; Butler WM; Adamovich E; Allen Z; Anderson R; Wallner KE
BJU Int; 2008 Jun; 101(12):1524-9. PubMed ID: 18325064
[TBL] [Abstract][Full Text] [Related]
2. Short-term functional outcomes and complications associated with transperineal template prostate mapping biopsy.
Tsivian M; Abern MR; Qi P; Polascik TJ
Urology; 2013 Jul; 82(1):166-70. PubMed ID: 23697794
[TBL] [Abstract][Full Text] [Related]
3. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
4. Acute urinary retention after transperineal template-guided prostate biopsy.
Buskirk SJ; Pinkstaff DM; Petrou SP; Wehle MJ; Broderick GA; Young PR; Weigand SD; O'Brien PC; Igel TC
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1360-6. PubMed ID: 15275721
[TBL] [Abstract][Full Text] [Related]
5. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate.
Bittner N; Merrick GS; Stewart R; Andreini H; Taubenslag W; Curtis R; Butler WM; Wallner KE
Urol Oncol; 2011; 29(4):398-404. PubMed ID: 19945303
[TBL] [Abstract][Full Text] [Related]
6. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
7. [Complications of transperineal template-guided prostate mapping biopsy].
Wang F; Ding XF; Xu JN; Xu YZ; Zhou YQ; Luan Y; Lu SM; Tao HZ
Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(6):428-431. PubMed ID: 30786336
[No Abstract] [Full Text] [Related]
8. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
9. The incidence of transition zone prostate cancer diagnosed by transperineal template-guided mapping biopsy: implications for treatment planning.
Patel V; Merrick GS; Allen ZA; Andreini H; Taubenslag W; Singh S; Butler WM; Adamovich E; Bittner N
Urology; 2011 May; 77(5):1148-52. PubMed ID: 21334045
[TBL] [Abstract][Full Text] [Related]
10. The impact of transrectal prostate needle biopsy on sexuality in men and their female partners.
Tuncel A; Kirilmaz U; Nalcacioglu V; Aslan Y; Polat F; Atan A
Urology; 2008 Jun; 71(6):1128-31. PubMed ID: 18372025
[TBL] [Abstract][Full Text] [Related]
11. Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.
Bittner N; Merrick GS; Butler WM; Galbreath RW; Anderson RL; Adamovich E; Wallner KE
Brachytherapy; 2012; 11(3):219-23. PubMed ID: 21820364
[TBL] [Abstract][Full Text] [Related]
12. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity.
Beekman M; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW
Urology; 2005 Dec; 66(6):1266-70. PubMed ID: 16360455
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of transperineal template guided mapping biopsy for therapeutic decision making in low risk prostate cancer.
Ahallal Y; Sanchez-Salas R; Sivaraman A; Barret E; Secin FP; Validire P; Rozet F; Galiano M; Cathelineau X
Actas Urol Esp; 2016 Dec; 40(10):615-620. PubMed ID: 27527686
[TBL] [Abstract][Full Text] [Related]
14. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy.
Bittner N; Merrick GS; Butler WM; Bennett A; Galbreath RW
J Urol; 2013 Aug; 190(2):509-14. PubMed ID: 23416641
[TBL] [Abstract][Full Text] [Related]
15. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.
Fujita K; Landis P; McNeil BK; Pavlovich CP
J Urol; 2009 Dec; 182(6):2664-9. PubMed ID: 19836757
[TBL] [Abstract][Full Text] [Related]
16. Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study.
Miah S; Eldred-Evans D; Simmons LAM; Shah TT; Kanthabalan A; Arya M; Winkler M; McCartan N; Freeman A; Punwani S; Moore CM; Emberton M; Ahmed HU
J Urol; 2018 Dec; 200(6):1235-1240. PubMed ID: 29940251
[TBL] [Abstract][Full Text] [Related]
17. Correlation between lower urinary tract symptoms and erectile dysfunction in men presenting for prostate cancer screening.
Reggio E; de Bessa J; Junqueira RG; Timm O; Sette MJ; Sansana V; Gomes CM
Int J Impot Res; 2007; 19(5):492-5. PubMed ID: 17554395
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy.
Helfand BT; Glaser AP; Rimar K; Zargaroff S; Hedges J; McGuire BB; Catalona WJ; McVary KT
BJU Int; 2013 Jan; 111(1):38-43. PubMed ID: 22639942
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of Initial Transperineal Template-guided Mapping Biopsy of the Prostate Gland.
Bittner N; Merrick GS; Bennett A; Butler WM; Andreini HJ; Taubenslag W; Adamovich E
Am J Clin Oncol; 2015 Jun; 38(3):300-3. PubMed ID: 23764680
[TBL] [Abstract][Full Text] [Related]
20. Extensive transperineal template biopsies of prostate: modified technique and results.
Bott SR; Henderson A; Halls JE; Montgomery BS; Laing R; Langley SE
Urology; 2006 Nov; 68(5):1037-41. PubMed ID: 17095067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]